The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Biomarkers In Barrett's Oesophagus And Oesophageal Adenocarcinoma
Funder
National Health and Medical Research Council
Funding Amount
$67,690.00
Summary
Barrett’s oesophagus (BO) is a condition in which the normal lining of the lower oesophagus is replaced with intestine-like tissue as a response to long-standing acid reflux. BO can progress to oesophageal adenocarcinoma (OAC), an aggressive cancer with poor 5-year survival rates of ~15%. This project aims at detecting genetic and molecular changes that occur in both BO and OAC and which may help predict the risk of progression as well as survival for patients affected by this disease entity.
PRECISION: Personalised Risk Evaluation In DCIS, International
Funder
National Health and Medical Research Council
Funding Amount
$1,392,930.00
Summary
Ductal carcinoma in situ (DCIS) of the breast is a common diagnosis with problematic clinical management. This study brings together an international consortium to identify and validate clinical biomarkers of recurrence.
Circulating Tumour DNA As A Personalized Biomarker In ER Positive Metastatic Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$124,676.00
Summary
This PhD aims to study the use of liquid biopsies for disease monitoring in metastatic estrogen receptor positive breast cancer. Liquid biopsies involve looking for circulating cancer-specific genetic material in the blood stream. Through the use of liquid biopsies, we hope to understand genetic differences and heterogeneity within metastatic breast cancer; identify potential therapeutic targets; and examine the mechanisms of treatment resistance to facilitate personalised cancer therapy.
Molecular Characterisation Of Early Precursor Lesions Of A Novel Ñserrated Pathwayî Of Colorectal Cancer Using Gene Expression And Proteomics.
Funder
National Health and Medical Research Council
Funding Amount
$318,338.00
Summary
In Australia, CRC is the second highest cause of all cancer-related deaths. If detected early, CRC has a high success rate of cure, but a percentage of precursor lesions escape detection and show aggressive clinical behaviour to progress to CRC. These are difficult to diagnosis with existing technologies. We aim to understand the biology behind sessile serrated adenoma pathways and hence enhance early detection, diagnosis and treatments strategies.
PET Imaging Agents For The Differential Diagnosis Of Hypoxic Tumors
Funder
National Health and Medical Research Council
Funding Amount
$585,429.00
Summary
Choosing the best type of treatment from the ever increasing arsenal of chemotherapeutic agents against cancer is of critical importance. Tumor hypoxia requires specialized treatment and patient selection. Current PET imaging agents cannot differentiate between severely and mildly hypoxic tumors. We have found a new agent that can detect mildly hypoxic tumors and the aim of this grant application is to further develop this radiotracer to improve image quality and reliability of the diagnosis.